PL3332800T3 - Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP - Google Patents

Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP

Info

Publication number
PL3332800T3
PL3332800T3 PL18153676T PL18153676T PL3332800T3 PL 3332800 T3 PL3332800 T3 PL 3332800T3 PL 18153676 T PL18153676 T PL 18153676T PL 18153676 T PL18153676 T PL 18153676T PL 3332800 T3 PL3332800 T3 PL 3332800T3
Authority
PL
Poland
Prior art keywords
methods
variable domains
single variable
immunoglobulin single
treating ttp
Prior art date
Application number
PL18153676T
Other languages
English (en)
Polish (pl)
Inventor
Christian DUBY
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PL3332800T3 publication Critical patent/PL3332800T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18153676T 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP PL3332800T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof
EP18153676.4A EP3332800B1 (en) 2014-06-16 2015-06-16 Immunoglobulin single variable domains for use in methods of treating ttp
EP15729829.0A EP3154569B1 (en) 2014-06-16 2015-06-16 Immunoglobulin single variable domains for use in treating ttp

Publications (1)

Publication Number Publication Date
PL3332800T3 true PL3332800T3 (pl) 2021-04-19

Family

ID=51541255

Family Applications (5)

Application Number Title Priority Date Filing Date
PL18153676T PL3332800T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP
PL18153671T PL3366305T3 (pl) 2014-06-16 2015-06-16 Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania
PL18153674.9T PL3335724T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL15729829T PL3154569T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
PL18153673.1T PL3335723T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL18153671T PL3366305T3 (pl) 2014-06-16 2015-06-16 Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania
PL18153674.9T PL3335724T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL15729829T PL3154569T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
PL18153673.1T PL3335723T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3366305B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102403388B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2881331T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3332800T3 (enExample)
PT (5) PT3366305T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG10201811109PA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
AU2019217584B2 (en) * 2018-02-06 2025-08-14 Ablynx Nv Methods of treating initial episode of TTP with immunoglobulin single variable domains
IL302984A (en) * 2020-11-18 2023-07-01 Green Cross Corp Adamts13 variant having increased escaping rate or activity against autoantibody
EP4402165A1 (en) 2021-09-17 2024-07-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023108095A1 (en) * 2021-12-10 2023-06-15 Emory University Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
BRPI0406694B8 (pt) 2003-01-10 2021-05-25 Ablynx Nv polipeptídios terapêutico, seus homólogos, seus fragmentos, que são usados nas modulações da agregação plaquetária
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
CA2535550A1 (en) 2003-08-12 2005-03-03 William M. Yarbrough Treatment for acne vulgaris and method of use
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
ATE473446T1 (de) 2005-01-14 2010-07-15 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
JP2010518839A (ja) 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
WO2008142164A2 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2009227055A1 (en) 2008-03-21 2009-09-24 Ablynx Nv Von Willebrand Factor specific binders and methods of use therefor
BRPI0919979A2 (pt) 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
AU2012267458A1 (en) 2011-06-10 2014-01-09 Baxalta GmbH Treatment of coagulation disease by administration of recombinant VWF
KR102162413B1 (ko) 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
AU2019217584B2 (en) 2018-02-06 2025-08-14 Ablynx Nv Methods of treating initial episode of TTP with immunoglobulin single variable domains

Also Published As

Publication number Publication date
US12269893B2 (en) 2025-04-08
PL3335724T3 (pl) 2022-09-19
CN106559985A (zh) 2017-04-05
IL249540A0 (en) 2017-02-28
PL3366305T3 (pl) 2021-06-14
EP3335723B1 (en) 2022-03-30
PT3332800T (pt) 2020-11-19
JP2020097600A (ja) 2020-06-25
NL2013007B1 (en) 2016-07-05
US10858445B2 (en) 2020-12-08
AU2015276237B2 (en) 2021-02-25
ES2843642T3 (es) 2021-07-19
ES2831865T3 (es) 2021-06-09
JP6688746B2 (ja) 2020-04-28
US10919980B2 (en) 2021-02-16
EP3335724B1 (en) 2022-06-22
US20170210822A1 (en) 2017-07-27
KR102403388B1 (ko) 2022-06-03
US20180155443A1 (en) 2018-06-07
PL3335723T3 (pl) 2022-07-18
HK1256730A1 (en) 2019-10-04
EP3154569A1 (en) 2017-04-19
EP3335724A1 (en) 2018-06-20
KR20220053040A (ko) 2022-04-28
RU2019131713A (ru) 2019-11-11
JP7105260B2 (ja) 2022-07-22
RU2017100077A3 (enExample) 2018-12-25
AU2015276237A1 (en) 2017-01-19
PT3366305T (pt) 2020-12-21
RU2704444C2 (ru) 2019-10-28
EP3332800B1 (en) 2020-08-26
PT3335723T (pt) 2022-05-20
IL249540B (en) 2021-09-30
US20180155441A1 (en) 2018-06-07
SG11201610488QA (en) 2017-01-27
US20180155442A1 (en) 2018-06-07
PT3154569T (pt) 2021-06-22
ES2881331T3 (es) 2021-11-29
EP3332800A1 (en) 2018-06-13
AU2021202747B2 (en) 2024-02-15
KR102568585B1 (ko) 2023-08-18
JP2017519762A (ja) 2017-07-20
PT3335724T (pt) 2022-08-02
PL3154569T3 (pl) 2021-11-02
EP3154569B1 (en) 2021-04-21
JP2022160431A (ja) 2022-10-19
HK1256731A1 (en) 2019-10-04
RU2017100077A (ru) 2018-07-12
CA2952103A1 (en) 2015-12-23
EP4059513A1 (en) 2022-09-21
ES2924199T3 (es) 2022-10-05
AU2021202747A1 (en) 2021-05-27
HK1258508A1 (en) 2019-11-15
WO2015193326A1 (en) 2015-12-23
ES2915473T3 (es) 2022-06-22
EP3366305A1 (en) 2018-08-29
EP3366305B1 (en) 2020-11-18
KR20170015513A (ko) 2017-02-08
US20180155440A1 (en) 2018-06-07
EP3335723A1 (en) 2018-06-20
SG10201811109PA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
IL281755A (en) Enhanced variable complexes of immunoglobulins
IL247898A0 (en) Anti-ox40 antibodies and methods of use
IL252008A0 (en) Methods for producing bispecific domains, variants of antibodies and their use
ES3043078T3 (en) Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
PT3332800T (pt) Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
IL265568A (en) Methods for treating TIM-3 elevation
HK1236434A1 (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof